Abstract
Invasive fungal infections are major complications of stem cell transplantation associated with significant morbidity and mortality. Allogeneic stem cell transplant recipients are at a significantly greater risk for fungal infection than recipients of autologous transplantation. Although with the wide use of fluconazole prophylaxis the incidence and associated mortality of invasive candidiasis has been minimized, mold diseases remain a significant complication during periods of prolonged immunosuppression for graft versus host disease. Posaconazole prophylaxis during periods of high risk was recently demonstrated to be effective in preventing fungal infections and associated mortality. Preemptive strategy employing laboratory markers and serial CT scans to identify mold infection at an early stage is promising. However its efficacy has to be validated in clinical trials. Several new antifungal agents have been introduced lately, characterized by improved safety profile and broader antifungal spectrum. Voriconazole has become the standard of care for the treatment of invasive aspergillosis. Finally there has been increasing interest on combination therapy for invasive aspergillosis due to the high rate of failure of the currently available antifungals, especially in the profoundly immunocompromised host.
Keywords: Yeast, Mold, Candida, Aspergillus, Zygomycetes, Fusarium, Stem cell transplantation
Current Pharmaceutical Design
Title: Antifungal Agents in Hematopoietic Stem Cell Transplantation
Volume: 14 Issue: 20
Author(s): G. Iyer Parameswaran, Brahm H. Segal and Nikolaos G. Almyroudis
Affiliation:
Keywords: Yeast, Mold, Candida, Aspergillus, Zygomycetes, Fusarium, Stem cell transplantation
Abstract: Invasive fungal infections are major complications of stem cell transplantation associated with significant morbidity and mortality. Allogeneic stem cell transplant recipients are at a significantly greater risk for fungal infection than recipients of autologous transplantation. Although with the wide use of fluconazole prophylaxis the incidence and associated mortality of invasive candidiasis has been minimized, mold diseases remain a significant complication during periods of prolonged immunosuppression for graft versus host disease. Posaconazole prophylaxis during periods of high risk was recently demonstrated to be effective in preventing fungal infections and associated mortality. Preemptive strategy employing laboratory markers and serial CT scans to identify mold infection at an early stage is promising. However its efficacy has to be validated in clinical trials. Several new antifungal agents have been introduced lately, characterized by improved safety profile and broader antifungal spectrum. Voriconazole has become the standard of care for the treatment of invasive aspergillosis. Finally there has been increasing interest on combination therapy for invasive aspergillosis due to the high rate of failure of the currently available antifungals, especially in the profoundly immunocompromised host.
Export Options
About this article
Cite this article as:
Parameswaran Iyer G., Segal H. Brahm and Almyroudis G. Nikolaos, Antifungal Agents in Hematopoietic Stem Cell Transplantation, Current Pharmaceutical Design 2008; 14 (20) . https://dx.doi.org/10.2174/138161208785061391
DOI https://dx.doi.org/10.2174/138161208785061391 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Adrenomedullin and Oxidative Stress in Vascular Damage and Metabolic Disease
Current Hypertension Reviews Unsafe Abortion: The Silent Endemic; An Avoidable Cause of Maternal Mortality. A Review
Current Women`s Health Reviews Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Rho Kinase Inhibitors and Novel Ocular Drug Delivery Systems- A Revolutionary Step Towards the Treatment of Glaucoma
Current Drug Delivery Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery Bone Disease in Diabetes
Current Diabetes Reviews Downregulation of Membrane-bound Angiotensin Converting Enzyme 2 (ACE2) Receptor has a Pivotal Role in COVID-19 Immunopathology
Current Drug Targets Histamine as a Potential Adjuvant to Immuno and Radiotherapy for Cancer Treatment: Discovering New Functions for the Oldest Biogenic Amine
Current Immunology Reviews (Discontinued) Therapeutic Options for Transfusion Related Acute Lung Injury; the Potential of the G2A Receptor
Current Pharmaceutical Design Future Directions in the Treatment of Neuropathic Pain: A Review on Various Therapeutic Targets
CNS & Neurological Disorders - Drug Targets Magnetic Digital Microfluidics for Point-of-Care Testing: Where Are We Now?
Current Medicinal Chemistry Activated Carbon/MoO<sub>3</sub>: Efficient Catalyst for Green Synthesis of Chromeno[<i>d</i>]pyrimidinediones and Xanthenones
Combinatorial Chemistry & High Throughput Screening Triphala in Prevention of Dental Caries and as an Antimicrobial in Oral Cavity- A Review
Infectious Disorders - Drug Targets Pathophysiological Roles of Renin-Angiotensin System on Erythropoietic Action
Current Hypertension Reviews Genetics and Personalized Medicine in Antidepressant Treatment
Current Pharmaceutical Design Adrenocortical Crisis Triggered by Levothyroxine in an Unrecognized Autoimmune Polyglandular Syndrome Type-2: A Case Report with Review of the Literature
Current Drug Safety B-Type Natriuretic Peptide: Endogenous Regulator of Myocardial Structure, Biomarker and Therapeutic Target
Current Molecular Medicine Safety of Canagliflozin in Patients with Type 2 Diabetes
Current Drug Safety The Cardiovascular Effects of Metformin: Further Reasons to Consider An Old Drug as a Cornerstone in the Therapy of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Current Developments in the Therapeutic Potential of S-Nitrosoglutathione, an Endogenous NO-Donor Molecule
Current Pharmaceutical Biotechnology